InvestSMART

Oncosil Medical Limited (ASX:OSL)

ALERT: Price-sensitive ASX Announcement for OSL
Current share price for OSL : $1.080 0.645 (148.28%)+
Announcement
Release
9 Jun 2026 9:47AM
Price at Release
$0.435
Full Release
download
Summary
OncoSil Medical Limited announced that their TRIPP-FFX clinical trial has successfully met its co-primary endpoints of safety/tolerability and local disease control rate (LDCR) at 16 weeks for patients with unresectable locally advanced pancreatic cancer (LAPC). The study demonstrated that adding the OncoSil™ device to the standard FOLFIRINOX chemotherapy regimen resulted in an 82.2% LDCR and 18.3 months median overall survival with manageable toxicities. These outcomes confirm the safety and efficacy of OncoSil™ in improving treatment outcomes for LAPC. The company plans to submit regulatory filings to expand the CE Mark to include FOLFIRINOX as an additional chemotherapy option, aiming to enhance the availability and adoption of OncoSil™ in clinical practice.
Key Points
  • TRIPP-FFX study meets safety and LDCR co-primary endpoints at 16 weeks.
  • OncoSil™ combined with FOLFIRINOX shows 82.2% LDCR and 18.3 months median overall survival.
  • Toxicities were limited and manageable.
  • The trial was non-comparative, using historical controls for efficacy evaluation.
  • OncoSil Medical plans regulatory submissions to expand the use of OncoSil™ with FOLFIRINOX.
  • Successful integration of OncoSil™ with FOLFIRINOX could simplify patient pathways and support adoption.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.